NEW research, presented at the European Academy of Dermatology and Venereology Congress (EADV) Congress 2024 in Amsterdam, the Netherlands, investigates the efficacy of semaglutide, a GLP-1 receptor agonist, in treating hidradenitis suppurativa (HS), a chronic skin condition prevalent in obese individuals
They also have a role in diabetic neuropathies, a side effect of diabetes that damages the brain[11]
Xu S, Hao K, Xiong Y, Xu R, Huang H, Wang H
It reduces appetite, leading to significant weight loss, which is a critical factor in reducing the risk of obesity-related conditions such as cardiovascular disease, certain cancers, and type 2 diabetes itself
If you notice reduced effectiveness despite adherence, consult your healthcare provider about potential dose adjustment or other contributing factors